Skip to main content
SpringerLink
Log in

Unexpected response of extramedullary plasmacytoma in patients with lung cancer who received nivolumab

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Dores GM, Landgren O, McGlynn KA, Curtis RE, Linet MS, Devesa SS (2009) Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol 144:86–94

    Article  Google Scholar 

  2. Shih LY, Dunn P, Leung WM, Chen WJ, Wang PN (1995) Localised plasmacytomas in Taiwan: comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone. Br J Cancer 71:128–133

    Article  CAS  Google Scholar 

  3. Radman I, Sucić M, Serventi-Seiwerth R, Boban D, Marković-Glamocak M, Ries S, Gjadrov-Kuvezdić K, Petković D, Jakić-Razumović J, Sćukanec-Spoljar M, Seiwerth S, Sucić Z, Papa J (2005) Patient with immunoproliferative disease and lung carcinoma: a case report. Diagn Cytopathol 32(2):97–102

    Article  Google Scholar 

  4. Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J (2016) Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol 34:2698–2704

    Article  CAS  Google Scholar 

  5. Yamaguchi O, Kaira K, Hashimoto K, Mouri A, Miura Y, Shiono A, Nishihara F, Murayama Y, Noda SE, Kato S, Kobayashi K, Kagamu H (2019) Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab. Thorac Cancer T 10:992–1000

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Respiratory Medicine, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka, 350-1298, Japan

    Ou Yamaguchi, K. Kaira & H. Kagamu

  2. Department of Hematology, Saitama Medical University Hospital, Saitama, Japan

    Y. Nakamura

Authors
  1. Ou Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Kaira
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Kagamu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ou Yamaguchi.

Ethics declarations

Conflict of interest

OY has received speaker honorarium from Ono Pharmaceutical Company and Bristol-Myers Company. KK has received speaker honorarium from Ono Pharmaceutical Company and Bristol-Myers Company. YN has received speaker honorarium from Ono Pharmaceutical Company and Bristol-Myers Company. HK has received speaker honorarium from Ono Pharmaceutical Company and Bristol-Myers Company.

Ethical approval

All procedures performed studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the patient in this case report.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yamaguchi, O., Kaira, K., Nakamura, Y. et al. Unexpected response of extramedullary plasmacytoma in patients with lung cancer who received nivolumab. Ann Hematol 98, 2851–2852 (2019). https://doi.org/10.1007/s00277-019-03832-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-019-03832-6

Search

Navigation